Knowledge on how to adjust a drug dose in special patient populations such as (prematurely born) neonates or children, critically-ill patients, obese individuals, or pregnant women, is not only crucial for novel compounds but also for existing drugs which are often used in an off-label manner.
- Catherijne Knibbe
Through combining the statistical power of the population approach with physiologically-based approaches in these special populations both the pharmacokinetics and pharmacodynamics of drugs, and the associated inter-individual variability, can be characterized.
Ultimately, these efforts should lead to quantitative clinical pharmacology models that can predict in each individual patient the efficacy and safety of the drug studied, and potentially of other (related) drugs.
Connection with other research
- Clinical Pharmacology
- From Descriptive to Predictive Pharmacology in Children using Semi-Physiological population modelling
- From descriptive to predictive pharmacology in children using semi-physiological population modelling: application to hepatic metabolism
- Predictive value of semi-physiological models for clearance of renally excreted drugs across the paediatric age range
- Population PKPD analysis within the “DINO-Trial” evaluating the pharmacokinetics and pharmacodynamics of routinely used off-label drugs in premature neonates
- Pharmacodynamics of analgesics and sedatives in neonates and infants
- Individualized dosing of aminoglycosides and glycopeptide antibiotics in (morbidly) obese patients (AMIGO)
- Cytochrome P450 3A-mediated first-pass and systemic drug metabolism in children
- Pharmacokinetic studies in obese adolescents and obese adults
- Systems pharmacology-based optimization of postoperative morphine treatment